Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: CDMO Sector - The company has a constructive outlook on CDMO enterprises due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - Ratings for WuXi AppTec (02359, 603259.SH) and WuXi Biologics (02268) have been upgraded to "Buy" [1] Group 2: Biotech and Pharmaceutical Companies - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech (06990), Innovent Biologics (02696), and Hansoh Pharmaceutical (03692) are viewed positively [1] Group 3: Medical Devices Sector - The company maintains a neutral view on the medical devices sector, noting that while the industry has bottomed out, recovery will take time [1] - Recommendations include buying Angelalign Technology (06699) and Weigao Group (01066) [1] Group 4: Medical Services Sector - A relatively cautious stance is held regarding the medical services sector due to ongoing cost control measures and a weak consumer cycle [1] - The rating for Haijia Medical (06078) has been downgraded to "Neutral" [1]

Core Insights - The Hong Kong Stock Exchange Technology 100 Index (HKEXT100) has risen by 1.14% as of January 5, 2026, with most of the top ten weighted stocks showing positive performance [1] - The index tracks the performance of the 100 largest technology companies listed on the Hong Kong Stock Exchange, covering six major innovative themes [1] - The launch of the HKEXT100 index highlights the key role of the Hong Kong market in promoting the development of emerging industries [1] Stock Performance - Kuaishou-W increased by 10.87% - Innovent Biologics rose by 6.15% - BeiGene gained 5.47% - WuXi Biologics went up by 3.69% - Alibaba-W saw an increase of 2.48% - SMIC rose by 2.33% - Tencent Holdings increased by 0.48% - Meituan-W decreased by 0.10% - BYD Company fell by 1.87% - Xiaomi Group-W dropped by 2.33% [1] Index Features - The HKEXT100 index includes companies involved in artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [1] - All constituent stocks meet the qualifications for southbound trading, providing investors with an effective and comprehensive investment tool [1] - The index aims to help investors seize opportunities in technology and emerging sectors [1]

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has launched the HKEX Technology 100 Index, marking a significant milestone in its index and data business development, reflecting the transformation of the Hong Kong market towards a technology-centric identity [1][2]. Group 1: Introduction of the Technology 100 Index - The HKEX Technology 100 Index is a broad-based stock index tracking the performance of the 100 largest technology companies listed on the HKEX, covering six major innovative themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [2][3]. - The index includes only stocks eligible for the Stock Connect program, catering to both international and mainland Chinese investors [2]. Group 2: Market Trends and Investor Sentiment - There has been a noticeable shift in investor perception of the Hong Kong market, increasingly recognizing it as a technology-driven market, especially since the listing rule reforms initiated in 2018 [3]. - Data indicates a significant change in the market structure, with the market capitalization of technology stocks in the Stock Connect program rising from approximately 10% in 2014 to about 40% by 2025, with four out of the top ten companies being technology giants [3]. Group 3: Differentiation from Existing Indices - The HKEX Technology 100 Index differentiates itself from the Hang Seng Technology Index by including 100 constituent stocks, ranging from large-cap companies like Tencent and Alibaba to smaller firms with market capitalizations of over 20 billion HKD [5][6]. - The index aims to meet diverse investor needs, providing a broader selection of technology stocks compared to existing indices [6]. Group 4: Future Developments and Performance - The HKEX plans to introduce more indices, including thematic indices, to further enhance its product offerings [8]. - The HKEX Technology 100 Index has shown strong performance, with a cumulative return of approximately 40% year-to-date, and returns of 45% and 55% over the past year and three years, respectively, highlighting the growth potential of the technology sector in the Hong Kong market [9].

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has launched the Hong Kong Stock Exchange Technology 100 Index, marking a significant milestone in its index and data business development, reflecting a fundamental shift in the market structure towards technology as a key sector [1][2]. Group 1: Introduction of the Technology 100 Index - The Technology 100 Index tracks the performance of 100 of the largest technology companies listed on the HKEX, covering six major innovative themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [1]. - The index is designed to meet the investment needs of both international and mainland Chinese investors, as all constituent stocks are eligible for the Stock Connect program [1]. Group 2: Market Trends and Investor Demand - There has been a notable shift in investor perception of the Hong Kong market, increasingly recognizing it as a technology-driven market, especially since the listing rule reforms initiated in 2018 [2]. - Data indicates that the market structure has transitioned from traditional industries to being dominated by technology companies, with the market capitalization of technology stocks in the Stock Connect increasing from approximately 10% in 2014 to about 40% by 2025 [2]. Group 3: Differentiation from Existing Indices - The Technology 100 Index differentiates itself from the Hang Seng Technology Index by including 100 constituent stocks, ranging from large-cap companies like Tencent and Alibaba to smaller firms with market capitalizations of over 200 million HKD [3]. - This broader coverage aims to cater to diverse investor needs, enhancing the overall attractiveness of the market [4]. Group 4: Accessibility and Future Developments - All constituent stocks of the Technology 100 Index must meet the eligibility criteria for Stock Connect, ensuring ease of access for mainland fund companies [5]. - The index has a mechanism for rapid inclusion of representative new stocks, allowing it to reflect market dynamics promptly [5]. - Future plans for the HKEX include the introduction of more indices, including thematic indices, to meet growing investor demand [5].

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has launched the Hong Kong Stock Exchange Technology 100 Index, marking a significant milestone in its index and data business development, reflecting a fundamental shift in the market structure towards technology as a key sector [1][2]. Group 1: Introduction of the Technology 100 Index - The Technology 100 Index tracks the performance of 100 of the largest technology companies listed on the HKEX, covering six major innovative themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [1]. - The index is designed to meet the investment needs of both international and mainland Chinese investors, as all constituent stocks are eligible for the Stock Connect program [1][2]. Group 2: Market Trends and Investor Interest - There has been a noticeable shift in investor perception of the Hong Kong market, increasingly recognizing it as a technology-driven market, especially since the listing rule reforms initiated in 2018 [2]. - Data indicates that the market structure has transitioned from traditional industries to being dominated by technology companies, with the market capitalization of technology stocks in the Stock Connect program expected to rise from approximately 10% in 2014 to about 40% by 2025 [2]. Group 3: Differentiation from Existing Indices - The Technology 100 Index differentiates itself from the Hang Seng Technology Index by including 100 constituent stocks, ranging from large-cap companies like Tencent and Alibaba to smaller firms with market capitalizations of over 20 billion HKD [3]. - The index aims to cater to diverse investor needs, providing a broader range of investment options compared to existing indices [3]. Group 4: Accessibility and Inclusion Criteria - All constituent stocks of the Technology 100 Index must meet the eligibility criteria for the Stock Connect program, ensuring ease of access for mainland fund companies [4]. - The index requires constituent stocks to have at least six months of listing history, but it also includes a rapid inclusion mechanism for representative new stocks that meet the criteria [4]. Group 5: Future Developments and Performance - The HKEX plans to introduce more indices, including thematic indices, to meet growing investor demand [5]. - The Technology 100 Index has shown strong performance, with a cumulative return of approximately 40% year-to-date as of November 30, 2025, and returns of 45% and 55% over the past year and three years, respectively, highlighting the growth potential of the technology sector in the Hong Kong market [5].

Core Viewpoint - The Hong Kong Stock Exchange has launched the Hong Kong Stock Exchange Technology 100 Index, which tracks the performance of the 100 largest technology companies listed on the exchange [1] Group 1: Index Overview - The Hong Kong Stock Exchange Technology 100 Index is the first index of its kind for Hong Kong stocks, focusing on major technology firms [1] - The index covers six major innovation themes: artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and smart driving, information technology, internet, and robotics [1] Group 2: Constituent Stocks - Initial constituent stocks of the Technology 100 Index include major companies such as Tencent Holdings, Alibaba, Xiaomi Group, and Meitu [1] - The index features a rapid inclusion mechanism, allowing newly listed companies that meet specific criteria to be added outside the regular review cycle after being included in the Hong Kong Stock Connect trading [1]

Core Viewpoint - The healthcare stocks in mainland China have experienced a significant pullback since early last month, with the Hang Seng Healthcare Index and the CSI 300 Healthcare Index declining by 12% and 9% respectively, compared to a 2% drop in the Hang Seng Index and a 1% increase in the CSI 300 Index [1] Group 1: Market Influences - The decline in healthcare stocks is attributed to multiple factors, including heightened US-China tensions and increased geopolitical risk premiums prompting profit-taking by investors [1] - The introduction of a milder version of the US "Biosecurity Act" attached to next year's National Defense Authorization Act has raised uncertainties regarding pharmaceutical outsourcing services [1] - Concerns persist regarding potential increased regulation from the US, such as restrictions on authorized transactions with China or limitations on clinical data from China, which could impact the biotech and pharmaceutical sectors [1] Group 2: Market Sentiment and Valuation - The anticipated outcomes of the national medical insurance drug list price negotiations and the legislative progress of the "Biosecurity Act" are expected to influence market sentiment [1] - Despite the recent stock price declines, industry valuations and market expectations for business development transactions are returning to more reasonable levels, with no substantial deterioration in the industry's fundamental performance observed [1] - The recent pullback in stock prices may provide favorable conditions for performance in the upcoming year [1] Group 3: Preferred Stocks - The company identifies preferred stocks including CanSino Biologics (09926), Hansoh Pharmaceutical (03692), and WuXi AppTec (603259) (02359) [1] - The company also expresses optimism for Innovent Biologics (01801) and Heng Rui Medicine (600276) (01276) [1]